Exploring triazole-based drugs: Synthesis, application, FDA approvals, and clinical trial updates–A comprehensive review

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 735 citations · Full text

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

Maria Domenica Cappellini · Blood · 2005 · 713 citations · Full text

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Harold J. Burstein, Christina Lacchetti, Holly Anderson et al. · Journal of Clinical Oncology · 2018 · 610 citations

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

Megan Whitnall, Jonathan Howard, Prem Ponka et al. · Proceedings of the National Academy of Sciences · 2006 · 507 citations · Full text

Chemoprevention Strategy, Pathology, Wide Spectrum +20